Search the Newsreel

ARCT|Arcturus Therapeutics Holdings Inc|Price:5.530|Chg%:-0.260

This article provides a financial summary of Arcturus Therapeutics Holdings Inc (ARCT), detailing its latest earnings report from May 7, 2026, and presenting historical quarterly and annual financial metrics. It covers key indicators such as EPS, revenue, net profit, various margins, and balance sheet …

Arcturus Therapeutics Holdings Inc. Revenue Breakdown – NASDAQ:ARCT

This article provides a revenue breakdown for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT). Last year, the company generated $82.03 million USD, primarily from its Messenger Ribonucleic Acid Medicines segment, and the largest contribution came from the United States. This marks a decrease from $152.31 …

Why High Arctic Energy Services Inc. stock went up yesterday

Arcturus Therapeutics Holdings Inc (ARCT) Earnings, Actual EPS, EPS Estimates & Results

This article provides detailed earnings information for Arcturus Therapeutics Holdings Inc (ARCT), including its upcoming Q2 '26 earnings report, estimated EPS and revenue, and historical quarterly earnings data. It highlights past performance against estimates, showing both beats and misses. Additionally, the article includes recent …

Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

Arcturus Therapeutics Holdings Inc. announced it will present at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 12:00 p.m. ET. The company, an mRNA medicines developer, specializes in liver and respiratory rare disease therapeutics using LUNAR lipid-mediated delivery and …

Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20

Roth MKM has reiterated its Buy rating on Arcturus Therapeutics (ARCT.US) and maintained its target price at $20. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

What's Going On With High Arctic Energy Services Inc. Stock Wednesday?

Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?

Price to earnings forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT

ARCT Forecast — Price Target — Prediction for 2027

Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings: EPS Beat on Reduced Losses Despite No Revenue - Dividend Increase Stocks

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates

Arcturus Therapeutics (ARCT) Reports Progress in Q1 2026 Earnings Call

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Earnings call transcript: Arcturus Therapeutics Q1 2026: EPS Beat, Revenue Decline

Arcturus Therapeutics Holdings Inc (ARCT) Q1 2026 Earnings Report Preview: What To Expect

Arcturus Therapeutics Stock Plunges Over 58% Today: What’s Causing The Sell-Off?

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings

What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q3 2025 Earnings

The Market Doesn't Like What It Sees From Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Revenues Yet As Shares Tumble 52%

Arcturus Therapeutics (ARCT): Evaluating Valuation After Cystic Fibrosis Trial Setback and Heightened Regulatory Scrutiny

Arctic Blue Beverages

Arcturus Therapeutics (ARCT) Earnings Date and Reports 2026 $ARCT